[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"biomarker-discovery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:biomarker-discovery":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100652303","multimodal-biomarkers-in-coronary-artery-disease-pathogenesis-the-oxford-acute-myocardial-infarction-study-oxami-study-100652303",false,"NCT07772570","Multimodal Biomarkers in Coronary Artery Disease Pathogenesis: The Oxford Acute Myocardial Infarction Study (OXAMI Study)","OXAMI","Inclusion Criteria:\n\n* Evidence of myocardial injury (e.g. elevation of troponin or other cardiac biomarkers, ECG changes, wall motion abnormalities on cardiac imaging) AND\u002FOR referred for coronary angiography with view to proceed to PCI as indicated in either non-emergency or emergency settings.\n\nExclusion Criteria:\n\n* Patients in whom safety or clinical concerns preclude participation.\n* Anaemia (Hb \\\u003C9).\n* Pregnant or breast feeding females.\n\nAdditional exclusion criteria for patients undergoing MRI\n\n* claustrophobia which limits \u002F prevents participants from remaining in MRI scanner.\n* patients who cannot lie flat on the scan table.\n* patients with metallic implants, pacemakers, implantable defibrillators etc, unless known to be MRI compatible.\n* patients with known allergy to medium of contrast (gadolinium)\n\nAdditional exclusion criteria for patients undergoing coronary CT angiography\n\n* patients with a known allergy to iodinated contrast media\n* eGFR\\\u003C 30 ml\u002Fmin (stage 3-5 renal disease)",true,"ALL","18 Years","90 Years",{"count":21,"type":22},2000,"ESTIMATED","20 Years","OBSERVATIONAL","Coronary artery disease is one of the most common causes of illness and death. It develops when fatty deposits, known as plaques, build up in the arteries that supply blood to the heart. These plaques can gradually narrow the arteries and reduce blood flow, causing symptoms such as chest pain (angina). Sometimes a plaque can suddenly break open, causing a blood clot to form and block the artery. This can lead to a heart attack and permanent damage to the heart muscle.\n\nAlthough much has been learned about coronary artery disease, important questions remain about why some plaques suddenly become unstable, how this affects blood flow through the smallest blood vessels of the heart, and why some patients develop more heart muscle damage than others.\n\nThe Oxford Acute Myocardial Infarction (OxAMI) research programme aims to improve our understanding of these processes. We will study both the disease within the coronary arteries (the \"upstream\" problem) and its effects on the heart muscle (the \"downstream\" damage). By examining these together, we hope to understand more clearly how changes in coronary plaques lead to heart injury and how this differs between patients.\n\nPatients undergoing procedures to investigate or treat coronary artery disease provide an important opportunity to study these processes. During coronary angioplasty (also called percutaneous coronary intervention or PCI), a narrow or blocked artery is opened, usually using a small balloon and a stent. This procedure can disturb the underlying plaque in a similar way to the plaque disruption that occurs during a heart attack. Where appropriate, we may therefore collect blood and material released from the plaque during these procedures. Blood may be collected from different locations in the circulation, allowing us to study substances released by the plaque and heart muscle. Material that would otherwise be discarded during treatment may also be collected for laboratory analysis.\n\nWe will use several established and newer techniques to examine the coronary arteries, the small blood vessels within the heart, and the heart muscle. These may include detailed imaging from inside the coronary arteries using intravascular ultrasound (IVUS) or optical coherence tomography (OCT). We may also measure blood pressure and flow within the coronary arteries to assess how well the small blood vessels supplying the heart are working.\n\nNon-invasive heart scans may include cardiovascular magnetic resonance (CMR\u002FMRI), cardiac computed tomography (CT) and echocardiography (ultrasound). These techniques can provide detailed information about the structure and function of the heart, blood supply to the heart muscle, areas of injury or permanent scarring, and changes that occur following a heart attack. In particular, MRI may help distinguish heart muscle that has been permanently damaged from muscle that is injured but could potentially recover after blood flow is restored. This may be especially important for patients who arrive at hospital several hours after their heart attack began.\n\nOther measurements may include electrocardiograms (ECGs), which record the electrical activity of the heart, and measurements of heart pressure, volume and function. Some participants may also have longer-term ECG monitoring.\n\nBlood and tissue samples may be analysed using a range of laboratory techniques. These studies will investigate inflammation, blood clotting and other biological processes involved in coronary artery disease and heart attacks. Newer laboratory methods may allow us to measure large numbers of proteins and small molecules in the blood. Material collected from plaques may also be examined under a microscope to identify its cells and structural components.\n\nWith additional consent, blood samples may be stored for genetic research. This could help us understand whether differences in people's genes influence their risk of coronary artery disease, their response to a heart attack, or the amount of heart damage that occurs.\n\nBy combining information about coronary plaques, blood flow through the heart's circulation, heart muscle injury, imaging, blood and tissue markers, and genetic factors, OxAMI aims to build a detailed picture of coronary artery disease and heart attacks. The programme will establish a carefully characterised group of research participants who may contribute to future OxAMI studies conducted under separate research protocols.\n\nUltimately, this research aims to identify better ways to predict, diagnose and understand coronary artery disease and heart attacks, and to identify new approaches that could improve treatment and outcomes for future patients.",[27,28,29,30,31,32,33,34,35],"Myocardial Injury","Atherosclerosis Cardiovascular Disease","Cardiac Imaging Techniques","Genetics","Thrombus","Trained Immunity","Biomarker Discovery","Coronary Physiology","Intravascular Imaging and Microvascular Obstruction","RECRUITING","2026-08-14",{"date":39,"type":40},"2026-08-19","ACTUAL",{"date":42,"type":40},"2012-05",{"date":44,"type":22},"2046-12",{"name":46,"class":47},"University of Oxford","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":24,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":48},"100644641","t6a-biomarker-for-detection-of-bacterial-infection-in-newborn-infants-100644641","NCT07670624","T6A Biomarker for Detection of Bacterial Infection in Newborn Infants","T6ASepsis","Inclusion Criteria:\n\n* Newborn infants who require blood testing for screening for bacterial infection OR treating physician suspects bacterial infection in newborn infant\n* Signed informed consent form\n\nExclusion Criteria:\n\n1. Refusal to participate in study or not providing written informed consent by caregivers\u002Fparents\n2. Antibiotic treatment of any kind.",{"count":57,"type":22},210,"1 Week","This study aims to assess the efficacy of a new biomarker, N6-threonylcarbamoyladenosine (t6A), for the early diagnosis of Early-Onset Sepsis (EOS) in newborns.",[61,62,33],"Sepsis","Newborn Sepsis",[64,65,66,67],"t6a","newborn sepsis","infectious disease biomarker","biomarker","NOT_YET_RECRUITING","2026-08-13",{"date":71,"type":40},"2026-08-17",{"date":73,"type":22},"2026-09-01",{"date":75,"type":22},"2029-01-31",{"name":77,"class":47},"Salzburger Landeskliniken",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":16,"sex":17,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":89,"conditions":90,"keywords":95,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100612447","epigut-epilepsy-and-gastrointestinal-microbiota-understanding-therapy-response-100612447","NCT07253701","EPIGUT: EPILEPSY AND GASTROINTESTINAL MICROBIOTA: UNDERSTANDING THERAPY RESPONSE","EpiGUT","Inclusion Criteria:\n\n* Patients: Age 2-79 years, newly diagnosed with epilepsy, treatment-naive at time of enrollment\n* Controls: Age 2-79 years\n\nExclusion Criteria:\n\n* Patients: already started ASM treatment (more then one dose), has used antibiotics or probiotics in the last three months, has a gastrointestinal diagnosis, has surgically removed parts of the GIT, obesity (BMI\\>30), T2D, follows a strict exclusion diet, is pregnant or breastfeeding, has a gastrostomy, PEG or jejunostomy\n* Controls: previous epilepsy diagnosis or ASM treatment, has used antibiotics or probiotics in the last three months, has a gastrointestinal diagnosis, has surgically removed parts of the GIT, obesity (BMI\\>30), T2D, follows a strict exclusion diet, is pregnant or breastfeeding, has a gastrostomy, PEG or jejunostomy","2 Years","79 Years",{"count":88,"type":22},1500,"The goal of this observational study is to learn how the bacteria in the gut and mouth (called the microbiota) are linked to different types of epilepsy and how they may affect how well seizure medicines work.\n\nResearchers want to answer two main questions:\n\nAre certain types of epilepsy linked to changes in the gut or mouth microbiota? Do the bacteria in the gut change how seizure medicines work for each person?\n\nEpilepsy is a brain condition that causes seizures. Even though there are many medicines for epilepsy, some people still have seizures or side effects. Studies in animals show that gut bacteria can raise or lower the chance of seizures. Smaller studies in people suggest the same thing, but they have been limited in size and scope.\n\nIn this study, researchers will collect biological samples from people who have newly diagnosed epilepsy and from people without epilepsy (called healthy controls). The samples will be tested to learn which bacteria are present. The researchers will then look for patterns that may explain which types of epilepsy are linked to changes in the microbiota.\n\nThe study will also look at whether the bacteria in the gut and mouth affect how well anti-seizure medicines (ASMs) work. For example, the researchers will explore if certain bacteria make medicines work better or worse.\n\nPatients will provide blood, stool and saliva samples. If collected for medical reasons, cerebrospinal fluid (CSF) - the clear liquid that surrounds the brain and spinal cord -will also be used.\n\nHealthy controls will provide stool and saliva samples only\n\nAll participants will be asked to fill an online questionnaire to share health and lifestyle information.\n\nPatients also allow researchers to confidentially access data from medical records related to diagnosis and treatment.\n\nBy comparing data from many participants across Sweden, researchers hope to understand how gut and mouth bacteria influence epilepsy and seizure control.\n\nThis research may help doctors in the future to use a person's microbiota profile to choose the best seizure medicine. The long-term goal is to improve seizure control, reduce side effects, and raise the quality of life for people living with epilepsy.",[91,92,93,94,33],"Epilepsy","Microbiota","Proteomics","Metabolomics",[96,97,98,99,100],"seizures","microbiome","anti-seizure medication","gut-brain-axis","epilepsy","2025-11-19",{"date":103,"type":40},"2025-11-28",{"date":105,"type":40},"2024-02-27",{"date":107,"type":22},"2028-03",{"name":109,"class":47},"Karolinska Institutet",6]